These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20975258)

  • 41. Allergic interstitial nephritis possibly related to sunitinib use.
    Khurana A
    Am J Geriatr Pharmacother; 2007 Dec; 5(4):341-4. PubMed ID: 18179992
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
    Chu TF; Rupnick MA; Kerkela R; Dallabrida SM; Zurakowski D; Nguyen L; Woulfe K; Pravda E; Cassiola F; Desai J; George S; Morgan JA; Harris DM; Ismail NS; Chen JH; Schoen FJ; Van den Abbeele AD; Demetri GD; Force T; Chen MH
    Lancet; 2007 Dec; 370(9604):2011-9. PubMed ID: 18083403
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
    Sato S; Muraishi K; Tani J; Sasaki Y; Tokubuchi I; Tajiri Y; Yamada K; Suekane S; Miyajima J; Matsuoka K; Hiromatsu Y
    Endocr J; 2010; 57(10):873-80. PubMed ID: 20733268
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib.
    Iacovelli R; Mancini ML; Risi E; Palazzo A; Cortesi E
    Int J Dermatol; 2012 Feb; 51(2):221-2. PubMed ID: 22250635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Tumor lysis syndrome in a patient with a renal carcinoma treated with sunitinib].
    Rodríguez-Reimúndes E; Perazzo F; Vilches AR
    Medicina (B Aires); 2011; 71(2):158-60. PubMed ID: 21550933
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nephrotoxicities associated with the use of tyrosine kinase inhibitors: a single-center experience and review of the literature.
    Jhaveri KD; Flombaum CD; Kroog G; Glezerman IG
    Nephron Clin Pract; 2011; 117(4):c312-9. PubMed ID: 21051905
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A case of pyoderma gangrenosum possibly associated with sunitinib treatment.
    Ueharaguchi Y; Kabashima K; Sasahashi M; Matsuda A; Matubara K; Matsui M
    Int J Dermatol; 2013 May; 52(5):634-6. PubMed ID: 23590380
    [No Abstract]   [Full Text] [Related]  

  • 48. Acute renal failure during the "off" period after sunitinib administration: possible mechanism of vascular endothelial growth factor cascade hyperactivation.
    Kato T; Tomita Y; Watanabe T
    Int J Urol; 2013 Nov; 20(11):1149-50. PubMed ID: 23659419
    [No Abstract]   [Full Text] [Related]  

  • 49. Early onset recall pneumonitis during targeted therapy with sunitinib.
    Yuasa T; Kitsukawa S; Sukegawa G; Yamamoto S; Kudo K; Miyazawa K; Kozuka T; Harada S; Yonese J
    BMC Cancer; 2013 Jan; 13():3. PubMed ID: 23282195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
    Jiménez-Gallo D; Albarrán-Planelles C; Linares-Barrios M; Martínez-Rodríguez A; Báez-Perea JM
    JAMA Dermatol; 2013 May; 149(5):624-6. PubMed ID: 23677103
    [No Abstract]   [Full Text] [Related]  

  • 51. Heart failure associated with sunitinib: lessons learned from animal models.
    Greineder CF; Kohnstamm S; Ky B
    Curr Hypertens Rep; 2011 Dec; 13(6):436-41. PubMed ID: 21826469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute renal failure: a rare side effect of sunitinib therapy.
    Kawsar HI; Bansal S; Myles JL
    Med Oncol; 2012 Dec; 29(5):3594-6. PubMed ID: 22684694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sunitinib induced colitis manifesting as invasive diarrhea in a patient with renal cell carcinoma.
    Gündoğdu Y; Deniz OC; Saka D; Şişman G; Erdamar S; Köksal İ
    J Oncol Pharm Pract; 2022 Mar; 28(2):516-518. PubMed ID: 34791942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of hemodialyzed patient with sunitinib.
    Reckova M; Kakalejcik M; Beniak J
    Ann Oncol; 2009 Feb; 20(2):392-3. PubMed ID: 19136449
    [No Abstract]   [Full Text] [Related]  

  • 55. Sunitinib therapy as a cause of diffuse digestive tract hemorrhage in end-stage renal disease patient.
    Taki Y; Imai N; Kojima S; Kaneshiro N; Shibagaki Y
    Saudi J Kidney Dis Transpl; 2018; 29(2):483-484. PubMed ID: 29657229
    [No Abstract]   [Full Text] [Related]  

  • 56. "Pseudocavitation" in thymic carcinoma during treatment with sunitinib.
    Tiseo M; Rajan A; Thomas A; Giaccone G
    J Thorac Oncol; 2013 Apr; 8(4):511-2. PubMed ID: 23486269
    [No Abstract]   [Full Text] [Related]  

  • 57. Rapid and life-threatening heart failure induced by pazopanib.
    Wang H; Rodriguez-Pla A; Campagna A
    BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30115717
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Colchicine toxicity precipitated by interaction with sunitinib.
    Abodunde OA; LevakaVeera RR; Desai R; Nweke N; Berrou M
    J Clin Pharm Ther; 2013 Jun; 38(3):243-5. PubMed ID: 23448320
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiotoxicity Monitoring in Patients Treated with Tyrosine Kinase Inhibitors.
    Skubitz KM
    Oncologist; 2019 Jul; 24(7):e600-e602. PubMed ID: 30971480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tyrosine kinase inhibitors and acute pancreatitis.
    Pezzilli R; Corinaldesi R; Morselli-Labate AM
    JOP; 2010 May; 11(3):291-3. PubMed ID: 20442535
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.